Efficacy and tolerance of dasatinib after imatinib failure or
intolerance for patients with chronic myeloid leukemia treated
in three different hospitals compare well with results
achievable in formal clinical trials.

J 2013

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.

ŽÁČKOVÁ, Daniela, Hana KLAMOVÁ, Jan MUŽÍK, Edmund CMUNT, Zdeněk RÁČIL et. al.

Základní údaje

Originální název

Autoři

ŽÁČKOVÁ, Daniela (203 Česká republika, garant, domácí), Hana KLAMOVÁ (203 Česká republika), Jan MUŽÍK (203 Česká republika, domácí), Edmund CMUNT (203 Česká republika), Zdeněk RÁČIL (203 Česká republika, domácí), Kateřina MACHOVÁ POLÁKOVÁ (203 Česká republika), Dana DVOŘÁKOVÁ (203 Česká republika, domácí), Tomáš JURČEK (203 Česká republika), Filip RÁZGA (703 Slovensko, domácí), Petr CETKOVSKÝ (203 Česká republika), Ladislav DUŠEK (203 Česká republika, domácí) a Jiří MAYER (203 Česká republika, domácí)

Vydání

Leukemia & Lymphoma, London, Informa Healthcare, Gordon and Breach, 2013, 1042-8194

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.605

Kód RIV

RIV/00216224:14740/13:00070872

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.3109/10428194.2013.772173

UT WoS

000324589800042

Klíčová slova anglicky

chronic myeloid leukemia; formal clinical trials; dasatinib; imatinib

Štítky

podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 4. 2014 09:58, Olga Křížová

Anotace

V originále

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.

Přiložené soubory

ZVV_1139161_Efficacy_and_tolerance.pdf

Požádat o autorskou verzi souboru

Citovat

ŽÁČKOVÁ, Daniela, Hana KLAMOVÁ, Jan MUŽÍK, Edmund CMUNT, Zdeněk RÁČIL, Kateřina MACHOVÁ POLÁKOVÁ, Dana DVOŘÁKOVÁ, Tomáš JURČEK, Filip RÁZGA, Petr CETKOVSKÝ, Ladislav DUŠEK a Jiří MAYER. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials. Leukemia & Lymphoma. London: Informa Healthcare, Gordon and Breach, 2013, roč. 54, č. 10, s. 2310-2313. ISSN 1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2013.772173.

@article{1139161,
   author = {Žáčková, Daniela and Klamová, Hana and Mužík, Jan and Cmunt, Edmund and Ráčil, Zdeněk and Machová Poláková, Kateřina and Dvořáková, Dana and Jurček, Tomáš and Rázga, Filip and Cetkovský, Petr and Dušek, Ladislav and Mayer, Jiří},
   article_location = {London},
   article_number = {10},
   doi = {http://dx.doi.org/10.3109/10428194.2013.772173},
   keywords = {chronic myeloid leukemia; formal clinical trials; dasatinib; imatinib},
   language = {eng},
   issn = {1042-8194},
   journal = {Leukemia & Lymphoma},
   title = {Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.},
   url = {http://informahealthcare.com/doi/abs/10.3109/10428194.2013.772173},
   volume = {54},
   year = {2013}
}

TY  - JOUR
ID  - 1139161
AU  - Žáčková, Daniela - Klamová, Hana - Mužík, Jan - Cmunt, Edmund - Ráčil, Zdeněk - Machová Poláková, Kateřina - Dvořáková, Dana - Jurček, Tomáš - Rázga, Filip - Cetkovský, Petr - Dušek, Ladislav - Mayer, Jiří
PY  - 2013
TI  - Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
JF  - Leukemia & Lymphoma
VL  - 54
IS  - 10
SP  - 2310-2313
EP  - 2310-2313
PB  - Informa Healthcare, Gordon and Breach
SN  - 10428194
KW  - chronic myeloid leukemia
KW  - formal clinical trials
KW  - dasatinib
KW  - imatinib
UR  - http://informahealthcare.com/doi/abs/10.3109/10428194.2013.772173
L2  - http://informahealthcare.com/doi/abs/10.3109/10428194.2013.772173
N2  - Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
ER  -

ŽÁČKOVÁ, Daniela, Hana KLAMOVÁ, Jan MUŽÍK, Edmund CMUNT, Zdeněk RÁČIL, Kateřina MACHOVÁ POLÁKOVÁ, Dana DVOŘÁKOVÁ, Tomáš JURČEK, Filip RÁZGA, Petr CETKOVSKÝ, Ladislav DUŠEK a Jiří MAYER. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials. \textit{Leukemia \&{} Lymphoma}. London: Informa Healthcare, Gordon and Breach, 2013, roč.~54, č.~10, s.~2310-2313. ISSN~1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2013.772173.

Podrobný výpis o publikaci